A study analyzing insurance claims data found similar risks between continued and non-continued GLP-1RA medication use during early pregnancy. The authors conclude that further research is needed to better understand the safety of GLP-1RAs in pregnancy due to imprecise estimates for rare outcomes.
Mazdutide, a GLP-1 receptor dual agonist, provides clinically meaningful weight reduction in Chinese adults with obesity. However, gastrointestinal adverse reactions are more common among those taking the drug compared to placebo.
A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.
Adults with both obesity and an autoimmune disease who took a GLP-1-based medication had fewer emergency department visits and lower mortality rates compared to those not taking the medication. The study analyzed data from over 26,000 adults treated in the OneFlorida+ network between 2014 and 2024.
A new study reveals how Philip Morris Companies Inc. used cigarette research and flavor engineering to design Lunchables, a successful ultra-processed food for children. The company's strategy was based on optimizing 'technical synergies' between tobacco and food divisions.
Researchers from Pennington Biomedical will showcase their latest findings on prevention, care, and cures for diabetes and obesity at the American Diabetes Association's 2026 Scientific Sessions. The sessions will highlight cutting-edge advancements driving progress in diabetes research and management.
The University of Texas at San Antonio has received significant funding from the Cancer Prevention and Research Institute of Texas to develop innovative cancer research technologies and treatments. The institution will focus on pressing cancers such as Ewing sarcoma, obesity-related endometrial cancer risk, and AI in clinical oncology.
Researchers at Pennington Biomedical published the first study to estimate pediatric obesity prevalence among US children and adolescents aged 5-18 years using the new Lancet Commission definitions. The study found that many children are already experiencing measurable health impairments associated with obesity.
The use of weight loss medications like semaglutide and tirzepatide could deepen existing health inequalities if patients lack access to nutrition advice, healthy food, and ongoing healthcare support. Researchers warn that poorer patients may face barriers to using these treatments safely and maintaining health improvements over time.
Researchers highlight latest developments in pathology, diagnosis, and treatment of MASLD and IPFD, revealing correlations with chronic diseases like liver cancer and pancreatic cancer. Innovative treatments, such as AI-driven approaches and organ-targeted therapies, show promise for precision prevention and therapy.
Weight loss after bariatric surgery is associated with better ability to cope with daily household tasks such as cleaning and grocery shopping. The study also found that maintaining weight loss for long periods results in improved functionality and independence. Patients who regained lost weight experienced poorer outcomes over time.
A study found that BMI significantly understates obesity levels in the US, with up to 50% of overweight individuals reclassified as obese under a new clinical definition. This highlights the need for healthcare providers to adopt this new measure to better identify and treat obesity-related health risks.
A new study found that nearly a quarter of adults with a normal weight BMI may still be at risk for obesity-related health complications. The research highlights the importance of considering multiple factors beyond body mass index (BMI) to accurately identify individuals at risk for these conditions.
Two new international studies found that healthy lifestyles can have a protective effect on childhood cancer survivors, reducing the risk of chronic health problems. The studies suggest that physical activity, a healthy weight, and other lifestyle factors can significantly reduce the burden of disease in adulthood.
Researchers found that obesity alters the biological changes in breast cancer cells, enabling them to survive and thrive. The study's findings could improve prediction and treatment of invasive breast cancer, reducing overtreatment and unnecessary treatments.
A new study found that drinking tomato-soy juice lowered pro-inflammatory proteins in healthy adults with obesity after four weeks. The findings hint at the juice's promise as a functional food that may help curb chronic inflammation and improve health outcomes for patients with pancreatitis.
Two studies suggest that weight loss after bariatric surgery reduces cancer risk in women, with insulin levels and genetic background playing key roles. Women carrying a specific FTO genetic variant showed significant breast cancer risk reduction.
A new study published in Nature Medicine finds that semaglutide improves weight loss and metabolic health outcomes in patients who do not respond well to bariatric surgery. Patients taking semaglutide showed significant weight loss from body fat, improved blood sugar levels, and better quality of life.
A new study reveals that metabolic dysfunction in offspring is caused by excess microRNA in sperm from obese fathers. After weight loss, these molecular marks disappear, and offspring develop normally. Research suggests that interventions promoting health and longevity may trigger an increase in this enzyme expression.
A low-calorie diet and behavioral support program significantly reduced weight in older patients with overweight and persistent atrial fibrillation at 8 months. The study found no safety concerns or impact on atrial fibrillation symptoms, cardiac remodeling, or need for further rhythm control interventions.
Researchers developed an AI framework, MouseMapper, to map disease-related changes in the entire mouse body. They found widespread inflammation and previously unrecognized damage to facial sensory nerves caused by obesity, which was also observed in human tissue.
Researchers identified a subgroup of patients who experience nearly twice the improvement in sleep apnea when treated with tirzepatide GLP-1. These strong responders have distinct characteristics, including severe upper-airway collapsibility and breathing control instability. The study aims to provide personalized treatment options for...
A new study published in eBioMedicine found that integrating measurements such as body fat percentage and waist circumference can help identify individuals at high risk of developing obesity-related diseases. The research team analysed data from 489,311 participants and found that those with an adverse adiposity profile despite normal ...
A research study, COACH trial, is testing different ways to help children and families improve their health through lifestyle changes delivered by primary care clinics. The study aims to assess the effectiveness of personalized nutrition counseling, community resources, and online interactive lessons on weight management.
Weight loss followed by weight regain, known as 'yo-yo dieting,' is not supported by strong scientific evidence. The authors found that benefits of losing weight outweigh the theoretical risks of weight cycling in most cases. Repeated attempts at weight loss can provide meaningful periods of improved metabolic health and quality of life.
The European Association for the Study of Obesity, dietitian societies, and patients' organizations have issued a new consensus statement on using incretin drugs to treat obesity. The statement highlights the importance of medical nutritional therapy (MNT) and reinforces healthy dietary patterns. It also emphasizes the need to monitor ...
A comparative study found that endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral semaglutide. Patients undergoing ESG achieved a mean total body weight loss of 12.7%, compared to 8.7% in those receiving semaglutide.
A nationwide self-controlled cohort study found that GLP-1 class of obesity drugs were associated with a 26% fall in asthma exacerbations and a 14% drop in use of asthma inhaler reliever. The study suggests that weight loss, modulation of airway inflammation, and improvements in metabolic functions may improve asthma outcomes.
A meta-analysis of 32 studies and 43,618 adults found a clinically relevant drop in blood pressure with obesity drugs for weight loss. The study shows that GLP-1RAs and MHRMs can induce significant BP reductions, with a 0.34 mmHg reduction per 1% weight loss.
A new study published at the European Congress on Obesity found that participants who underwent rapid weight loss lost significantly more weight than those who followed a gradual weight loss plan. After one year, the rapid weight loss group had achieved clinically meaningful weight loss and maintained it better than the gradual weight ...
A nationwide study in Denmark shows a 7% reduction in triptan use for migraine treatment among women taking semaglutide for weight loss, with no significant change observed among men. The study suggests that weight loss and potential direct effects of GLP-1RA treatments may contribute to reduced migraine medication use.
Two scientists, Dr. Anna Elizabeth Thalacker-Mercer and Dr. Rachel Whooten, receive awards for their groundbreaking research on micronutrients and muscle health in relation to aging and disease, as well as innovative approaches to childhood obesity care.
Research reveals bidirectional relationships between higher BMI and financial difficulties, loneliness and stress. Higher BMI may lead to stigma, social isolation and healthcare costs, while financial strain can limit access to healthy food and physical activity.
The article discusses how studying art history can aid in treating obesity, highlighting its long-standing depiction as a sign of prosperity and physical strength. Doctors can become more empathetic towards patients by understanding this historical context.
A new study suggests that GLP-1 receptor agonists and GIP/GLP-1 receptor agonists can lead to substantial fat loss while preserving skeletal muscle mass in relative terms. The study found that muscle mass remained stable over time when accounting for changes in fat mass.
New research links excessive weight gain across adulthood to increased risks of various obesity-related cancers, including liver and colon cancer. The study found that steeper weight gain was associated with higher incidence rates.
A randomised controlled trial found semaglutide (Wegovy) significantly reduced BMI by 19% and fat mass in young adults with severe obesity, improving metabolic syndrome severity. The study suggests GLP-1 based treatment as a promising option for managing severe obesity in young people resistant to prior hospital-based care.
A systematic review found that obesity surgeries resulted in a higher proportion of fat-free mass loss compared to diet and exercise interventions. Incretin-based obesity drugs also led to greater fat-free mass loss than traditional weight loss methods.
NUTRITION 2026 will feature new, unpublished research findings relevant to consumer choices, clinical practice and public policy. The meeting is the premier place to dig deep into the discourse on what we eat and why it matters.
Research found that people with obesity experience fewer pleasant emotions during exercise and are more likely driven by external motives. Positive emotional experiences and intrinsic motivational factors explain both physical activity levels and future exercise intentions.
A new study reveals a correlation between body weight and gut microbiota composition, which can lead to gastrointestinal diseases. However, genetics also play a role in shaping the gut microbiome.
Research by Dr. Hanim Diktas at Pennington Biomedical Research Center shows that combining GLP-1 receptor agonists with behavioral intervention leads to a greater reduction in 'food noise', a persistent thought about food disrupting daily life and healthy behaviors. The study found significant decreases in food noise for participants u...
New research finds that participants in the ATTAIN-MAINTAIN trial maintained a significant percentage of weight loss when switched from injectable tirzepatide or semaglutide to daily oral orforglipron treatment. The study shows that nearly all weight loss achieved on injectable therapies can be maintained by switching to oral therapies.
Patients on tirzepatide at maximum dose have seven times higher odds of maintaining weight loss compared to those who stop treatment. Those on the lower 5mg dose have four times higher odds, according to a new study published in The Lancet.
New research finds lift capacity signs across Europe are outdated, failing to reflect current obesity trends. The study suggests that modernizing these signs is crucial for maintaining safety and comfort, while also acknowledging limitations in the investigation.
The updated algorithm incorporates evidence from multiple randomised clinical trials, highlighting the strength of tirzepatide for weight loss and semaglutide for liver disease management. The new guidance also recommends semaglutide for metabolic dysfunction-associated steatohepatitis remission.
A cohort study found a potential association between GLP-1 RA use and improved survival rates among obese breast cancer patients with related metabolic conditions. Further evaluation of GLP-1 RA therapy in randomized clinical trials is warranted based on these findings.
A new study found that obesity-related changes in body fat send harmful signals to the brain, disrupting brain immune function and worsening Alzheimer's pathology. Restoring balance in phosphatidylethanolamines reduced lipid dysregulation, improved brain function and cognitive performance in Alzheimer's disease models.
A study of 65 countries found that consuming food away from home is consistently associated with obesity. Eating out is driven by sociodemographic factors such as sex, age, income, and education, and is linked to higher energy intake and body mass index.
A new post-hoc analysis examined daily oral orforglipron treatment for obesity, with or without diabetes, in users aged 65 years and over. The study found that orforglipron significantly reduced body weight and improved blood sugar markers compared to placebo, with a similar safety profile to the overall ATTAIN clinical trial population.
A pooled analysis of trials reveals semaglutide's safety and efficacy in individuals aged 65 years and older with obesity. The study found significant reductions in body weight and improvements in cardiometabolic risk factors, with a lower proportion of adverse events compared to placebo.
A new study found that reducing annual working hours by 1% is linked to a small decline in obesity rates across 33 OECD countries, with the impact being stronger for men than women. Higher income levels and urbanization also showed significant correlations with lower obesity prevalence.
The 'Ozempic Era' suggests a paradigm shift in understanding obesity, blaming commercial food systems rather than individual failings. Emerging medical data on GLP-1 agonists may drive policy responses to regulate ultra-processed foods.
The summit brought together endocrine leaders to identify opportunities to work closely together on increasing the visibility of endocrine health in policy decisions. Early findings from a workforce survey revealed challenges including long patient waiting times and retention concerns among early-career clinicians.
A new study found that patients who lost more weight with GLP-1 treatment had a lower risk of developing obesity-related conditions. In contrast, those who gained weight or only lost a small amount saw increased risks for osteoarthritis, chronic kidney disease, and heart failure.
A systematic review and meta-analysis of existing research found that increasing daily step count to around 8,500 can help prevent weight regain in people with overweight or obesity. Participants who increased their steps during the weight loss phase and maintained this level over time lost less weight and regained less weight.
The ECE 2026 brings together researchers and clinicians to share the latest endocrine research and developments. Key sessions include Plenaries, Symposia, Awards, Meet the Experts, Debates, and Oral Communications.
A study by the University of Gothenburg reveals that changes in gut bacteria composition after bariatric surgery are strongly associated with improved glucose metabolism and insulin release. Patients with type 2 diabetes who achieved improved glycemic control exhibited greater microbial gene richness and enhanced fermentation processes.
A new study found that bariatric surgery offers significantly greater protection against major adverse cardiovascular events compared to GLP-1 drugs. After five years, surgical patients were nearly 16% less likely to develop heart attacks, strokes, and deaths compared to those treated with GLP-1 drugs.
A study published in Cancer Medicine reveals that the same genes active in pancreatic cancer are also linked to obesity and diabetes, driving inflammatory and immune pathways. This discovery helps explain poorer cancer outcomes for those with metabolic disease and offers new avenues for targeted treatment.